Shenzhu Pingxiao formula treats allergic asthma through the HSP90AA1/MAPK14/PTGS2 pathway.

IF 1.3 4区医学 Q3 ALLERGY

Journal of Asthma Pub Date : 2025-10-03 DOI:10.1080/02770903.2025.2562582

Jinling Luan, Xiaoxia Zhang

{"title":"Shenzhu Pingxiao formula treats allergic asthma through the HSP90AA1/MAPK14/PTGS2 pathway.","authors":"Jinling Luan, Xiaoxia Zhang","doi":"10.1080/02770903.2025.2562582","DOIUrl":null,"url":null,"abstract":"Objective: Shenzhu Pingxiao formula is a classic Chinese medicinal prescription used for asthma. Given that its mechanism is unclear, this study aimed to evaluate anti-allergic asthma (AA) properties and predict the targets of Shenzhu Pingxiao formula.Methods: Mice were challenged using house dust mites (HDMs). The anti-AA effect of the formula was evaluated by the airway resistance and number of immune cells in bronchoalveolar lavage fluid (BALF). Network pharmacology and molecular docking were used to predict the targets. The real-time reverse-transcription PCR and western blot were applied to analyze key genes and proteins associated with IL-17 signaling pathway.Results: Administration of formula moderated the number of immune cells and reduced the airway hyperresponsiveness. Administration of formula reduced neutrophil recruitment. HSP90AA1, PTGS2, and MAPK14 involved in IL-17 signaling pathway, were predicted to be key targets for this formula. Vina scores in molecular docking were all ≤ -9 for wogonin-HSP90AA1, wogonin-MAPK14, and wogonin-PTGS2 pairs. Shenzhu Pingxiao formula decreased the expression levels of HSP90AA1, PTGS2, and MAPK14 in HDM-challenged mouse lung.Conclusions: Shenzhu Pingxiao formula can reduce neutrophil recruitment and exert anti-AA effects via suppression of HSP90AA1/MAPK14/PTGS2 pathway.","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-9"},"PeriodicalIF":1.3000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02770903.2025.2562582","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Shenzhu Pingxiao formula is a classic Chinese medicinal prescription used for asthma. Given that its mechanism is unclear, this study aimed to evaluate anti-allergic asthma (AA) properties and predict the targets of Shenzhu Pingxiao formula.

Methods: Mice were challenged using house dust mites (HDMs). The anti-AA effect of the formula was evaluated by the airway resistance and number of immune cells in bronchoalveolar lavage fluid (BALF). Network pharmacology and molecular docking were used to predict the targets. The real-time reverse-transcription PCR and western blot were applied to analyze key genes and proteins associated with IL-17 signaling pathway.

Results: Administration of formula moderated the number of immune cells and reduced the airway hyperresponsiveness. Administration of formula reduced neutrophil recruitment. HSP90AA1, PTGS2, and MAPK14 involved in IL-17 signaling pathway, were predicted to be key targets for this formula. Vina scores in molecular docking were all ≤ -9 for wogonin-HSP90AA1, wogonin-MAPK14, and wogonin-PTGS2 pairs. Shenzhu Pingxiao formula decreased the expression levels of HSP90AA1, PTGS2, and MAPK14 in HDM-challenged mouse lung.

Conclusions: Shenzhu Pingxiao formula can reduce neutrophil recruitment and exert anti-AA effects via suppression of HSP90AA1/MAPK14/PTGS2 pathway.

查看原文本刊更多论文

参助平消方通过HSP90AA1/MAPK14/PTGS2通路治疗过敏性哮喘。

参竹平喘方是治疗哮喘的经典中药方剂。鉴于其作用机制尚不明确，本研究旨在评价参竹平消方抗变应性哮喘的作用特性并预测其作用靶点。用室内尘螨（HDM）刺激小鼠。通过观察气道阻力及支气管肺泡灌洗液（BALF）免疫细胞数量，评价其抗变应性哮喘作用。利用网络药理学和分子对接技术预测靶点。应用实时反转录PCR和western blot分析IL-17信号通路相关的关键基因和蛋白。给药方可调节免疫细胞数量，降低气道高反应性。给药减少中性粒细胞招募。参与IL-17信号通路的HSP90AA1、PTGS2和MAPK14被预测为该公式的关键靶点。wogonin-HSP90AA1、wogonin-MAPK14、wogonin-PTGS2对分子对接Vina评分均≤-9。参助平消方降低hdm小鼠肺组织中HSP90AA1、PTGS2、MAPK14的表达水平。参术平消方通过抑制HSP90AA1/MAPK14/PTGS2通路，减少中性粒细胞募集，发挥抗过敏性哮喘作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Asthma 医学-过敏

CiteScore

4.00

自引率

5.30%

发文量

158

审稿时长

3-8 weeks

期刊介绍： Providing an authoritative open forum on asthma and related conditions, Journal of Asthma publishes clinical research around such topics as asthma management, critical and long-term care, preventative measures, environmental counselling, and patient education.